help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dordal, M. S.
Right arrow Articles by Goldwasser, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dordal, M. S.
Right arrow Articles by Goldwasser, E.

Endocrinology, Vol 116, 2293-2299, Copyright © 1985 by Endocrine Society

ARTICLES

The role of carbohydrate in erythropoietin action

MS Dordal, FF Wang and E Goldwasser

The carbohydrate composition of human erythropoietin (epo) was determined by micro-GLC. Enzymic removal of most of the sugars results in aggregation of glycosidase-treated epo, loss of biological activity when assayed in mice, and retention of activity when assayed in marrow cell cultures or by RIA. Endoglycosidase F causes the removal of most of the carbohydrates indicating that the oligosaccharides are asparagine linked. The lack of O-linked sugar is confirmed by the absence of N-acetylgalactosamine. These findings indicate that the oligosaccharide portion of epo, although required for action in vivo, is not required for interaction with the target cells of the blood- forming system.


This article has been cited by other articles:


Home page
 Br. J. Sports. Med.Home page
N Robinson, S Giraud, C Saudan, N Baume, L Avois, P Mangin, and M Saugy
Erythropoietin and blood doping
Br. J. Sports Med., July 1, 2006; 40(suppl_1): i30 - i34.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Engert
Recombinant human erythropoietin in oncology: current status and further developments
Ann. Onc., October 1, 2005; 16(10): 1584 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Farrell and A. Lee
The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues
Oncologist, November 1, 2004; 9(suppl_5): 18 - 30.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Skibeli, G. Nissen-Lie, and P. Torjesen
Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin
Blood, December 15, 2001; 98(13): 3626 - 3634.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
D. Cointe, R. Beliard, S. Jorieux, Y. Leroy, A. Glacet, A. Verbert, D. Bourel, and F. Chirat
Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties
Glycobiology, May 1, 2000; 10(5): 511 - 519.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
N. Casadevall, E. Dupuy, P. Molho-Sabatier, G. Tobelem, B. Varet, and P. Mayeux
Autoantibodies against Erythropoietin in a Patient with Pure Red-Cell Aplasia
N. Engl. J. Med., March 7, 1996; 334(10): 630 - 633.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society